Linden Lake Ventures

Linden Lake Ventures is a Bethesda, Maryland-based early-stage biotechnology-focused venture capital firm founded in 2019. It invests in biotechnology companies developing molecular medicines and seeks to support pre-clinical and phase I technologies, with an emphasis on oncology, immunology, hepatology, cardiovascular, respiratory, neurology, and orphan diseases. The firm takes a hands-on approach to help portfolio companies advance their programs.

Thomas Haag Ph.D

Managing Partner

2 past transactions

CrossBridge Bio

Seed Round in 2024
CrossBridge Bio is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) aimed at transforming cancer treatment. The company utilizes proprietary linker technology and enzymatic conjugation methods to create stable, targeted ADC therapeutics. This approach allows for enhanced efficacy and safety profiles, offering potential improvements in cancer therapy. CrossBridge Bio's commitment to innovation in ADC therapeutics positions it as a key player in the biotechnology sector, dedicated to advancing treatment options for patients with cancer.

Vesigen Therapeutics

Series A in 2020
Vesigen Therapeutics, established in 2020 and based in Cambridge, Massachusetts, specializes in developing innovative therapeutic products. The company's core technology, ARMMs (ARRDC1 Mediated Microvesicles), facilitates the delivery of various payloads such as RNAs, proteins, and gene-editing complexes directly into the cytoplasm of target cells. This approach overcomes intracellular delivery barriers, expanding the scope of treatable conditions and enabling new therapies for unmet medical needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.